We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.66%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$89.3B
AUM Growth
+$8.23B
(+10%)
Cap. Flow
+$1.9B
Cap. Flow
% of AUM
2.12%
Top 10 Holdings %
Top 10 Hldgs %
24.87%
Holding
4,460
New
1,490
Increased
1,679
Reduced
1,235
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$60.1M |
| 2 |
TSMC
TSM
|
+$59.1M |
| 3 |
Tesla
TSLA
|
+$56M |
| 4 |
Apple
AAPL
|
+$55.2M |
| 5 |
Amazon
AMZN
|
+$47.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI ACWI ex US ETF
ACWX
|
+$102M |
| 2 |
Everest Group
EG
|
+$27.4M |
| 3 |
Chevron
CVX
|
+$25M |
| 4 |
Wells Fargo
WFC
|
+$24.9M |
| 5 |
Crane NXT
CXT
|
+$13.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.27% |
| 2 | Healthcare | 12.98% |
| 3 | Financials | 12.17% |
| 4 | Consumer Discretionary | 11.18% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1776
Celldex Therapeutics
CLDX
$3.28B
| $2.5M | ﹤0.01% |
73,553
-371
| -0.5% | -$12.5K |
|
|
BRKL
1777
DELISTED
Brookline Bancorp
BRKL
| $2.5M | ﹤0.01% |
285,529
-17,908
| -6% | -$163K |
|
1778
Dorian LPG
LPG
$1.96B
| $2.49M | ﹤0.01% |
97,167
-1,293
| -1% | -$29.3K |
|
1779
WesBanco
WSBC
$4B
| $2.49M | ﹤0.01% |
97,104
+3,457
| +4% | +$90.1K |
|
|
LAZR
1780
DELISTED
Luminar Technologies
LAZR
| $2.48M | ﹤0.01% |
24,063
+2,421
| +11% | +$229K |
|
1781
Deluxe
DLX
$1.15B
| $2.48M | ﹤0.01% |
141,937
-2,474
| -2% | -$38.8K |
|
1782
Cytek Biosciences
CTKB
$546M
| $2.48M | ﹤0.01% |
290,422
+141,055
| +94% | +$1.27M |
|
|
DICE
1783
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $2.48M | ﹤0.01% |
53,286
-979
| -2% | -$33.8K |
|
1784
AerCap
AER
$23.8B
| $2.47M | ﹤0.01% |
+38,952
| New | +$2.25M |
|
1785
Standard Motor Products
SMP
$911M
| $2.47M | ﹤0.01% |
65,843
+1,369
| +2% | +$49.9K |
|
1786
Huron Consulting
HURN
$2.42B
| $2.47M | ﹤0.01% |
29,041
-1,146
| -4% | -$94K |
|
1787
National Healthcare
NHC
$3.38B
| $2.46M | ﹤0.01% |
39,861
+751
| +2% | +$44.5K |
|
1788
Adtran
ADTN
$616M
| $2.45M | ﹤0.01% |
232,890
+19,485
| +9% | +$193K |
|
1789
Q2 Holdings
QTWO
$3.92B
| $2.45M | ﹤0.01% |
79,193
+2,962
| +4% | +$77.6K |
|
1790
Southside Bancshares
SBSI
$967M
| $2.45M | ﹤0.01% |
93,506
-2,636
| -3% | -$76.7K |
|
|
MORF
1791
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $2.43M | ﹤0.01% |
42,410
+6,696
| +19% | +$350K |
|
|
HOUS
1792
DELISTED
Anywhere Real Estate
HOUS
| $2.42M | ﹤0.01% |
362,141
-3,092
| -0.8% | -$18.5K |
|
1793
New Fortress Energy
NFE
$101M
| $2.41M | ﹤0.01% |
90,003
+25,431
| +39% | +$737K |
|
1794
Fulgent Genetics
FLGT
$527M
| $2.41M | ﹤0.01% |
65,072
-811
| -1% | -$28.3K |
|
1795
Energy Recovery
ERII
$443M
| $2.4M | ﹤0.01% |
85,829
+13,246
| +18% | +$330K |
|
1796
Phreesia
PHR
$773M
| $2.39M | ﹤0.01% |
76,933
-3,266
| -4% | -$102K |
|
1797
Asana
ASAN
$2.13B
| $2.37M | ﹤0.01% |
107,655
+7,599
| +8% | +$152K |
|
1798
Thryv Holdings
THRY
$108M
| $2.37M | ﹤0.01% |
96,375
+7,961
| +9% | +$185K |
|
1799
JELD-WEN Holding
JELD
$164M
| $2.36M | ﹤0.01% |
134,594
+6,252
| +5% | +$87.1K |
|
1800
Cannae Holdings
CNNE
$649M
| $2.36M | ﹤0.01% |
116,746
+5,095
| +5% | +$97.8K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, RhumbLine Advisers held 4,460 positions worth $89.3B, up 10% from $81B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
RhumbLine Advisers's Q2 2023 filing shows 1,490 new, 1,679 increased, 1,235 reduced and 38 closed positions. Its largest new stake was TSMC: 635,517 shares worth $64.1M. The largest sale was iShares MSCI ACWI ex US ETF, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- RhumbLine Advisers's largest Q2 2023 buy was TSMC: 635,517 shares worth $64.1M.
- RhumbLine Advisers added most to Microsoft in Q2 2023, an estimated $60.1M increase.
- RhumbLine Advisers's biggest Q2 2023 reduction was iShares MSCI ACWI ex US ETF, cutting an estimated $102M.
- RhumbLine Advisers fully exited Everest Group in Q2 2023, selling an estimated $27.4M.
- RhumbLine Advisers's ten largest holdings make up 25% of its $89.3B portfolio in Q2 2023.
- RhumbLine Advisers opened 1,490 new positions and closed 38 in Q2 2023.
- RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $89.3B.
Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.